Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31407669 | 0.85 | AAK1 (0.35) | AAK1MMP13TDP1 | |
| SCHEMBL8598647 | 0.83 | AAK1 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL21447936 | 0.83 | AAK1 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL31407757 | 0.82 | AAK1 (0.36) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL4445820 | 0.82 | MMP13 (0.38) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL4452992 | 0.82 | MMP13 (0.38) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL25185703 | 0.82 | MMP13 (0.38) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL18686904 | 0.81 | ITGB3 (0.33) | AAK1MMP13KMT2A | |
| SCHEMBL31407666 | 0.79 | MMP13 (0.35) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL4705364 | 0.79 | AAK1 (0.36) | AAK1MMP13MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | AAK1 928/4885MMP13 3770/4885MEN1 492/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | AAK1 928/4885MMP13 3770/4885MEN1 492/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | AAK1 928/4885MMP13 3770/4885MEN1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.